Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Fluid biomarkers in multiple sclerosis, from current to future applications

  • Di Filippo, Massimiliano
  • Gaetani, Lorenzo
  • Centonze, Diego|||0000-0002-8390-8545
  • Hegen, Harald
  • Kuhle, Jens|||0000-0002-6963-8892
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Tintoré, Mar|||0000-0001-9999-5359
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Willemse, Eline A.J.|||0000-0001-9140-4243
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Parnetti, Lucilla|||0000-0001-5722-3967
Multiple sclerosis (MS) is an immune-mediated inflammatory and degenerative disorder of the central nervous system (CNS) with heterogeneous clinical manifestations. In the last decade, the landscape of cerebrospinal fluid (CSF) and blood biomarkers as potential key tools for MS diagnosis, prognosis and treatment monitoring has evolved considerably, alongside magnetic resonance imaging (MRI). CSF analysis has the potential not only to provide information on the underlying immunopathology of the disease and exclude differential diagnoses, but also to predict the risk of future relapses and disability accrual, guide therapeutic decisions and thus improve patient outcomes. This Series article overviews the biological framework and current applicability of fluid biomarkers for MS, exploring their potential role in the molecular characterisation of the disease. We discuss recent advances in the field of neurochemistry that enabled the detection of brain-derived proteins in blood, opening the door to much more efficient longitudinal disease monitoring. Furthermore, we identify the current challenges in the application of fluid biomarkers for MS in a real-world setting, while offering recommendations for harnessing their full potential as key paraclinical tools to improve patient management and personalise treatment.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease

  • Mishra, Neha
  • Scherer, Michael
  • Rosenstiel, Philip
Background and aims: Treatment with tumor necrosis factor α (TNFα) antagonists in IBD patients suffers from primary non-response rates of up to 40%. Biomarkers for early prediction of therapy success are missing. We investigated the dynamics of gene expression and DNA methylation in blood samples of IBD patients treated with the TNF antagonist infliximab and analyzed the predictive potential regarding therapy outcome. Methods: We performed a longitudinal, blood-based multi-omics study in two prospective IBD patient cohorts receiving first-time infliximab therapy (discovery: 14 patients, replication: 23 patients). Samples were collected at up to 7 time points (from baseline to 14 weeks after therapy induction). RNA-sequencing and genome-wide DNA methylation data were analyzed and correlated with clinical remission at week 14 as a primary endpoint. Results: We found no consistent ex ante predictive signature across the two cohorts. Longitudinally upregulated transcripts in the non-remitter group comprised TH2- and eosinophil-related genes including ALOX15, FCER1A, and OLIG2. Network construction identified transcript modules that were coherently expressed at baseline and in non-remitting patients but were disrupted at early time points in remitting patients. These modules reflected processes such as interferon signaling, erythropoiesis, and platelet aggregation. DNA methylation analysis identified remission-specific temporal changes, which partially overlapped with transcriptomic signals. Machine learning approaches identified features from differentially expressed genes cis-linked to DNA methylation changes at week 2 as a robust predictor of therapy outcome at week 14, which was validated in a publicly available dataset of 20 infliximab-treated CD patients. Conclusions: Integrative multi-omics analysis reveals early shifts of gene expression and DNA methylation as predictors for efficient response to anti-TNF treatment. Lack of such signatures might be used to identify patients with IBD unlikely to benefit from TNF antagonists at an early time point., Open Access funding enabled and organized by Projekt DEAL. This work was supported by the EU projects SYSCID (733100), IMI2 ImmUniverse (853995), the IMI2 Project 3TR (831434), the BMBF project iTREAT (01ZX1902A), and ExC 2167 Precision Medicine in Chronic Inflammation (RTF-VI).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Diagnostic performance of plasma Aß42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: an international multi-center study

  • Doecke, James D.
  • González Escalante, Armand
  • Contador, José
  • Suárez-Calvet, Marc
  • Fernández-Lebrero, Aida
  • Puig-Pijoan, Albert
  • Ortiz Romero, Paula, 1994-
  • Jiménez-Moyano, Esther
  • Minguillón, Carolina
  • Campo, Marta del
  • Teunissen, Charlotte E.
Introduction: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aß42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. Methods: Plasma samples (n = 1298) were collected from six international centers. Aß40, Aß42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut-off models. Results: p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aß- dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre-defined cut-offs. Discussion: p-tau181 was the best single plasma marker for detecting AD at any stage. Specific cut-offs are needed to maximize diagnostic performances. Highlights: Phosphorylated tau (p-tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co-pathology in frontotemporal dementia (FTD), p-tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD., O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens. L.G. participated on advisory boards for, and received writing honoraria and travel grants from, Almirall, Biogen, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, and Teva. Work at Lund University was supported by the European Research Council (ADG-101096455), Alzheimer's Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation (AF-980907), Swedish Brain Foundation (FO2021-0293), Parkinson foundation of Sweden (1412/22), Cure Alzheimer's fund, Rönström Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259), and Swedish federal government under the ALF agreement (2022-Projekt0080). The ALFA+ Study has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. M.S.-C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and ‘‘PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). Research of C.E.T. is supported by the European Commission (Marie Curie International Training Network), grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking [JU], grant No. 101034344) and JPND (bPRIDE), European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (22HLT07 NEuroBioStand), CANTATE project funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. C.T. is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). C.T. is recipient of TAP-dementia, a ZonMw funded project (#10510032120003) in the context of the Dutch National Dementia Strategy.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease

  • Garrido Trigo, Alba
  • Marchese, Domenica, 1986-
  • Caratù, Ginevra
  • Heyn, Holger
  • Salas, Azucena
Ulcerative colitis and Crohn's disease are chronic inflammatory intestinal diseases with perplexing heterogeneity in disease manifestation and response to treatment. While the molecular basis for this heterogeneity remains uncharacterized, single-cell technologies allow us to explore the transcriptional states within tissues at an unprecedented resolution which could further understanding of these complex diseases. Here, we apply single-cell RNA-sequencing to human inflamed intestine and show that the largest differences among patients are present within the myeloid compartment including macrophages and neutrophils. Using spatial transcriptomics in human tissue at single-cell resolution (CosMx Spatial Molecular Imaging) we spatially localize each of the macrophage and neutrophil subsets identified by single-cell RNA-sequencing and unravel further macrophage diversity based on their tissue localization. Finally, single-cell RNA-sequencing combined with single-cell spatial analysis reveals a strong communication network involving macrophages and inflammatory fibroblasts. Our data sheds light on the cellular complexity of these diseases and points towards the myeloid and stromal compartments as important cellular subsets for understanding patient-to-patient heterogeneity., This work was funded by grant PID2021-123918OB-I00 from MCIN/AEI/ 10.13039/501100011033 and co-funded by “FEDER A way to make Europe”. AM-C, VG and ID were funded by grant Grant #2008-04050 from The Leona and Harry B. Helmsley Charitable Trust. EM-A is funded by grant RH042155 (RTI2018-096946-B-I00) from Ministerio de Ciencia e Innovacion. IA-T is funded by grant 831434-2 (CE_IMI2-2018-14 call). HH received support for the project PID2020-115439GB-I00- funded by MCIN/AEI/10.13039/501100011033. This publication is part of a project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831434. This project also has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 848028.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma phosphorylated tau 217 to identify preclinical Alzheimer disease

  • Salvadó, Gemma
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Hansson, Oskar
Importance: Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective: To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, setting, and participants: This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures: Plasma p-tau217 levels measured by immunoassay. Main outcome and measures: Aβ status, determined by CSF or Aβ PET biomarkers. Results: Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P = .12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P < .001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P < .001). Conclusions and relevance: The findings highlight the potential of plasma p-tau217 as a stand-alone test-or when used in a sequential 2-step approach alongside PET or CSF testing-as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments., Work at the authors’ research center (Lund University) was supported by the National Institute of Aging (R01AG083740), European Research Council (ADG-101096455), Alzheimer’s Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775 and 2018-02052, 2021-02219), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg Foundation (2022-0231), Strategic Research Area MultiPark (multidisciplinary research in Parkinson’s disease) at Lund University, Swedish Alzheimer Foundation (AF-980907, AF-994229), Swedish Brain Foundation (FO2021-0293, FO2023-0163), Parkinson Foundation of Sweden (1412/22), Cure Alzheimer’s Fund, Rönström Family Foundation, Berg Family Foundation, Greta och Johan Kock Foundation, WASP and DDLS joint call for research projects (WASP/DDLS22-066), Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259), Bundy Academy at Lund University (2025-2026-2024-2428) and the Swedish federal government under the ALF agreement (2022-Projekt0080, 2022-Projekt0107). Dr Salvadó received funding from the European Union’s Horizon 2020 Research and Innovation Program under Marie Skłodowska-Curie action grant agreement number 101061836, an Alzheimer’s Association Research Fellowship (AARF-22-972612), the Brightfocus Foundation (A2024007F), the Alzheimerfonden (AF-980942, AF-994514, AF-1012218), Greta och Johan Kocks research grants and travel grants from the Strategic Research Area MultiPark (multidisciplinary research in Parkinson’s disease) at Lund University. This study was also funded by the Instituto de Salud Carlos III (Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España) through the projects INT21/00073, PI20/01473 and PI23/01786 to Dr Fortea) and the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Program 1, partly jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una Manera de Hacer Europa, and cofunded by the European Regional Development Fund/European Social Fund. This work was also supported by National Institutes of Health grants R01 AG056850; R21 AG056974, R01 AG061566, R01 AG081394, and R61AG066543 to Dr Fortea. It was also supported by Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to Dr Fortea) and Horizon 2020–Research and Innovation Framework Programme from the European Union (H2020-SC1-BHC-2018-2020 to Dr Fortea). Dr Suárez-Calvet received funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III and cofunded by the European Union; and from a fellowship from la Caixa Foundation (100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). The Translational Biomarkers in Aging and Dementia cohort is supported by the Weston Brain Institute, Canadian Institutes of Health Research (MOP-11-51-31; RFN 152985, 159815 and 162303), Canadian Consortium of Neurodegeneration and Aging (MOP-11-51-31-team 1), the Alzheimer’s Association (NIRG-12-92090 and NIRP-12-259245), Brain Canada Foundation (CFI Project 34874; 33397), the Fonds de Recherche du Québec–Santé (Chercheur Boursier, 2020-VICO-279314) and the Colin J. Adair Charitable Foundation. The Wisconsin Registry for Alzheimer's Prevention cohort was supported by R01AG027161, R01AG021155 and P30AG062715 from SC Johnson. The Australian Imaging Biomarkers and Lifestyle Study of Ageing study is funded by the Commonwealth Scientific and Industrial Research Organization, and the National Health and Medical Research Council. The Sant Pau Initiative on Neurodegeneration cohort received funding from the Fondo de Investigaciones Sanitario, Instituto de Salud Carlos III (PI21/00791, PI14/01126, PI17/01019, PI20/01473, PI13/01532, PI16/01825, PI18/00335, PI19/00882, PI18/00435, PI22/00611, INT19/00016, INT23/00048, PI17/01896, and AC19/00103), and the Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas program, jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa. The Sant Pau Initiative on Neurodegeneration cohort was also supported by the National Institutes of Health (grants 1R01AG056850-01A1; R21AG056974; and R01AG061566), by Generalitat de Catalunya (2017-SGR-547, SLT006/17/125, SLT006/17/119, SLT002/16/408), Marató TV3 Foundation grants 20141210, 044412 and 20142610, a grant from the Fundació Bancaria La Caixa (Down Alzheimer Barcelona Neuroimaging Initiative project), Fundació Catalana Síndrome de Down and Fundació Víctor Grífols i Lucas. Horizon 21 Consortium is partly funded by Jérôme Lejeune Foundation. PREVENT-AD was launched in 2011 as a $13.5 million, 7-year public-private partnership using funds provided by McGill University, the Fonds de Recherche du Québec–Santé, an unrestricted research grant from Pfizer Canada, the J.L. Levesque Foundation, the Lemaire Foundation, the Douglas Hospital Research Centre and Foundation, the Government of Canada, and the Canada Fund for Innovation. Additional funding sources include the Canadian Institutes of Health Research (438655), US National Institutes of Health (R01 AG068563), Alzheimer’s Association, Alzheimer Society of Canada and Brain Canada grants. Dr Blennow is supported by the Swedish Research Council (2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (AF-930351, AF-939721, AF-968270, and AF-994551), Hjärnfonden, Sweden (ALZ2022-0006 and FO2024-0048-TK-130), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (ALFGBG-965240 and ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer, the Kirsten and Freddy Johansen Foundation, and Familjen Rönströms Stiftelse. Dr Teunissen is supported by the European Commission (Marie Curie International Training Network, grant agreement 860197) and TAME, Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking, grant 101034344) and JPND (bPRIDE, CCAD), European Partnership on Metrology, cofinanced from the European Union’s Horizon Europe Research and Innovation Programme and by the participating states (22HLT07 NEuroBioStand). The CANTATE project was funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Michael J Fox Foundation, Health Holland, the Dutch Research Council, Alzheimer Drug Discovery Foundation, the Selfridges Group Foundation, and Alzheimer Netherlands. Dr Teunissen is also a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (73305095007) and Health~Holland, Topsector Life Sciences & Health (LSHM20106), and of TAP-dementia, a ZonMw-funded project (10510032120003) in the context of the Dutch National Dementia Strategy.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Molecular subtypes explain lupus epigenomic heterogeneity unveiling new regulatory genetic risk variants

  • Castellini-Pérez, Olivia
  • Povedano, Elena
  • Barturen, Guillermo
  • Martínez-Bueno, Manuel
  • Kerick, Martin
  • Marañón, Concepción
  • Martín, Javier
  • Ballestar, Estéban
  • Orietta Borghi, Maria
  • PRECISESADS Clinical Consortium
  • PRECISESADS Flow Cytometry Consortium
  • Carnero-Montoro, Elena
  • Alarcón-Riquelme, M. E.
PRECISEADS Clinical Consortium and PRECISEADS Flow Cytometry Study Group: et al., The heterogeneity of systemic lupus erythematosus (SLE) can be explained by epigenetic alterations that disrupt transcriptional programs mediating environmental and genetic risk. This study evaluated the epigenetic contribution to SLE heterogeneity considering molecular and serological subtypes, genetics and transcriptional status, followed by drug target discovery. We performed a stratified epigenome-wide association studies of whole blood DNA methylation from 213 SLE patients and 221 controls. Methylation quantitative trait loci analyses, cytokine and transcription factor activity - epigenetic associations and methylation-expression correlations were conducted. New drug targets were searched for based on differentially methylated genes. In a stratified approach, a total of 974 differential methylation CpG sites with dependency on molecular subtypes and autoantibody profiles were found. Mediation analyses suggested that SLE-associated SNPs in the HLA region exert their risk through DNA methylation changes. Novel genetic variants regulating DNAm in disease or in specific molecular contexts were identified. The epigenetic landscapes showed strong association with transcription factor activity and cytokine levels, conditioned by the molecular context. Epigenetic signals were enriched in known and novel drug targets for SLE. This study reveals possible genetic drivers and consequences of epigenetic variability on SLE heterogeneity and disentangles the DNAm mediation role on SLE genetic risk and novel disease-specific meQTLs. Finally, novel targets for drug development were discovered., Open access funding provided by Karolinska Institute., E.C.M and O.C.P have been funded by Grants for the financing of Research, Development, and Innovation (R + D + I) in Biomedicine and Health Sciences in Andalusia for the year 2021, project co-financed by 80% by funds of the FEDER Operational Program of Andalusia 2014-2020 (File Number: PECOVID-0072-2020). Funding for this work has been provided by the Plan Estatal, Ministerio de Ciencia e Innovación a MEAR No. PID2020-113776GB-I00, as well as to the Lupus Research Alliance/BMS Award to M.E.A.R. and the Diversity Supplement to O.C.P. Funding for the preparation of this manuscript has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no 115565, resources composed of the financial contribution from the European Union’s Seventh Framework Program (FP7/2007-2013) and the EFPIA companies’ in kind contribution and from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 831434 (3TR). The JU receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. The contributions of the consortia to this study are gratefully acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Neuroinflammation in Alzheimer disease

  • Heneka, Michael T.
  • Flier, Wiesje M. van der
  • Jessen, Frank
  • Hoozemanns, Jeroen
  • Thal, Dietmar Rudolf
  • Boche, Delphine
  • Brosseron, Frederic
  • Teunissen, Charlotte E.
  • Zetterberg, Henrik
  • Jacobs, Andreas H.
  • Edison, Paul
  • RamÍrez, Alfredo
  • Cruchaga, Carlos
  • Lambert, Jean-Charles
  • Ruíz Laza, Agustín
  • Sánchez-Mut, José Vicente
  • Fischer, Andre
  • Castro, Sergio
  • Stein, Thor D.
  • Kleineidam, Luca
  • Wagner, Michael
  • Neher, Jonas J.
  • Cunningham, Colm
  • Singhrao, Sim K.
  • Prinz, Marco
  • Glass, Christopher K.
  • Schlachetzki, Johannes C. M.
  • Butovsky, Oleg
  • Kleemann, Kilian
  • De Jaeger, Philip L.
  • Scheiblich, Hannah
  • Brown, Guy C.
  • Landreth, Gary
  • Moutinho, Miguel
  • Grutzendler, Jaime
  • Gomez-Nicola, Diego
  • McManus, Róisín M.
  • Andreasson, Katrin
  • Ising, Christina
  • Karabag, Deniz
  • Baker, Darren J.
  • Liddelow, Shane A.
  • Verkhratsky, Alexei
  • Tansey, Malu
  • Monsonego, Alon
  • Aigner, Ludwig
  • Dorothée, Guillaume
  • Nave, Klaus-Armin
  • Simons, Mikael
  • Constantin, Gabriela
  • Rosenzweig, Neta
  • Pascual Bravo, Alberto
  • Petzold, Gabor C.
  • Kipnis, Jonathan
  • Venegas, Carmen
  • Colonna, Marco
  • Walter, Jochen
  • Tenner, Andrea J.
  • O'Banion, M. Kerry
  • Steinert, Joern R.
  • Feinstein, Douglas L.
  • Sastre, Magdalena
  • Bhaskar, Kiran
  • Hong, Soyon
  • Schafer, Dorothy P.
  • Golde, Todd
  • Ransohoff, Richard M.
  • Morgan, David
  • Breitner, John
  • Mancuso, Renzo
  • Riechers, Sean-Patrick
Increasing evidence points to a pivotal role of immune processes in the pathogenesis of Alzheimer disease, which is the most prevalent neurodegenerative and dementia-causing disease of our time. Multiple lines of information provided by experimental, epidemiological, neuropathological and genetic studies suggest a pathological role for innate and adaptive immune activation in this disease. Here, we review the cell types and pathological mechanisms involved in disease development as well as the influence of genetics and lifestyle factors. Given the decade-long preclinical stage of Alzheimer disease, these mechanisms and their interactions are driving forces behind the spread and progression of the disease. The identification of treatment opportunities will require a precise understanding of the cells and mechanisms involved as well as a clear definition of their temporal and topographical nature. We will also discuss new therapeutic strategies for targeting neuroinflammation, which are now entering the clinic and showing promise for patients., A.F. received funds from Germany’s Excellence Strategy (EXC 2067/1 390729940). A.J.T. is supported by the National Institutes of Health (NIH) grant (U54 AG054349). D.L.F. is supported by grant IK6BX004852-01 from the Department of Veterans Affairs. D.B. acknowledges support from the Medical Research Council UK, Alzheimer’s Research UK and the European Union. She thanks the UK Brain Banks and BRAIN UK for providing tissue for her studies. D.J.B. is supported by the NIH (R01AG053229, R01AG068076, U54AG079779), the Minnesota Partnership for Biotechnology and Medical Genomics (MNP #18.04), and the Glenn Foundation for Medical Research. C.Cunningham is funded by the Irish Research Council, National Institutes of Health, the Dutch Research Council (ZonMW) and Alzheimer’s Research UK. D.G.-N. was supported by grants from the Medical Research Council (MR/P024572/1, MR/Y004116/1). C.V. was supported by the RYC2022-036191-I, funded by MCIN/AEI/10.13039/501100011033 and European Social Fund Plus. C.T. is supported by the European Commission Marie Curie International Training Network, grant agreement No. 860197 (MIRIADE) and TAME, Innovative Medicines Initiatives 3TR (Horizon 2020, grant No. 831434), EPND (IMI 2 Joint Undertaking (JU), grant No. 101034344) and JPND (bPRIDE, CCAD), European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (22HLT07 NEuroBioStand), CANTATE project funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Michael J Fox Foundation, Health Holland, ZonMW, Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, and Alzheimer Netherlands. C.T. is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). C.T. is a recipient of TAP-dementia, a ZonMw-funded project (#10510032120003) in the context of the Dutch National Dementia Strategy. D.M. is supported by ZEN24-1070221 from the Alzheimer’s Association and R01 AG055072, R01 AG077651, and P30 AG072931 from NIH. D.R.T. received support from Research Foundation – Flanders (FWO; G065721N), Stichting Alzheimer Onderzoek (SAO/FRA 2023/0009) and Alzheimer’s Association (22-AAIIA-963171). D.S. was supported by NINDS-R01NS117533, NIA-RF1AG068281 and NIH-R24OD036199. G.C. is supported by the NextGenerationEU and National Recovery and Resilience Plan, National Biodiversity Future Center and PE grant MNESYS (PE0000006). G.C.P. received funding from the German Science Foundation (PE1193/6-2), ERA-NET (MICRO-BLEEDs and TACKLE-CSVD), and the Fondation Leducq (Transatlantic Network of Excellence 23CVD03); he is a member of the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) excellence cluster ImmunoSensation2. G.D. thanks the Agence Nationale de la Recherche (grants #ANR-21-CE17-0054-01; #ANR-24-CE18-2770-02), Fondation Alzheimer, Fondation pour la Recherche Médicale, Fondation Pierre Deniker, Association France Alzheimer and Fondation Vaincre Alzheimer for funding his research. H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe Research and Innovation Programme under grant agreement No. 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320). J.B. was supported by a research grant from the Canada Institute for Health Research. J.G. was funded by the JPB Foundation, the Cure Alzheimers Fund and The Alzheimer’s Association. J.C.M.S. is supported by a clinical fellowship from the Alzheimer’s Association (AACSF). J.V.S.-M. is supported by grants from the Pasqual Maragall Foundation (PMRP/2022/1184) and Spanish (PID2022-143263OB-I00) and Valencian (PROMETEO/2021/045) governments. K.-A.N. has been supported by grants from the DFG (TRR274), European Research Council (ERC; AdG MyeliNANO) and the Adelson Medical Research Foundation (AMRF). K.B. was funded by the NIH grant RF1NS083704. L.A. is supppoted by the Austrian Science Fund FWF Project #P35417-B. K.A. is the Edward F. and Irene Thiele Pimley Professor of Neurology and Neurological Sciences and is supported by NIH grants RF1 AG070839, RF1 AG079131, and RF1 AG080742, the Wu Tsai Neurosciences Institute Knight Initiative for Brain Resilience at Stanford University, and she is a Chan Zuckerberg Biohub-San Francisco Investigator. M.K.O. is supported by grant 80NSSC21K0542 from NASA. O.B. is funded by grants from NIH-STTR (R41AG073059), Cure Alzheimer Fund, BrightFocus Foundation (2020A016806), NIH/NIA (R01 AG051812), NIH (R01 AG054672), NIH (R01 AG075509), NIH (R01 NS088137-10), NIH (R21AG076982), and NIH/NINDS (R01 NS088137). R.Mancuso has funding from the ERC under the European Union’s Horizon 2020 Research and Innovation Programme (project no. 101041867 - XenoMicrogliaAD), Fonds voor Wetenschappelijk Onderzoek (grants No. G0C9219N, G056022N and G0K9422N), the Alzheimer’s Association USA (2018-AARF-591110, 2018-AARF-591110-RAPID, E2A-23-1148152, ABA-22-968700). He also receives funding from BrightFocus Foundation (A2021034S), SAO-FRA (grants No. 2021/0021 and SAO-FRA 20230019) and the University of Antwerp (BOF-TOP 2022-2025). R.McManus is supported by grants from the European Union Joint Programme Neurodegenerative Disease (JPND) (01ED2409B), the Alzheimer’s Association (24AARF-1243474) and from the DFG, under Germany’s Excellence Strategy – EXC2151 – 390873048, along with Project-ID 432325352 – SFB 1454. S.C.G. is supported by the Alzheimer Forschung Initiative e.V (Grant 21060), the Hertie Network of Excellence in Clinical Neuroscience (Grant 2021-1A-12), the Bonn Neuroscience Clinician Scientist Program (Neuro-aCSis), and the DFG (EXC2151–390873048). S.H. is supported by the UK Dementia Research Institute (UKDRI-1011) and the Chan Zuckerberg Initiative Neurodegeneration Network. J.J.N. is currently supported through Germany’s Excellence Strategy (EXC 2145 SyNergy– ID 390857198), the Else Kröner-Fresenius Stiftung (2018-A158), the Charitable Hertie Foundation (P1200024), the BrightFocus Foundation (A2021035S) and Alzheimer’s Association (ADSF-24-1345513-C). W.M.vdF. performs research at the Alzheimer Center Amsterdam as part of the neurodegeneration research programme of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam. The chair held by W.M.vdF. is supported by the Pasman Stichting. W.M.vdF. is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). W.M.vdF. is a recipient of TAP-dementia (www.tap-dementia.nl), receiving funding from ZonMw (#10510032120003)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease

  • Garrido Trigo, Alba
  • Marchese, Domenica, 1986-
  • Caratù, Ginevra
  • Heyn, Holger
  • Salas, Azucena
Ulcerative colitis and Crohn's disease are chronic inflammatory intestinal diseases with perplexing heterogeneity in disease manifestation and response to treatment. While the molecular basis for this heterogeneity remains uncharacterized, single-cell technologies allow us to explore the transcriptional states within tissues at an unprecedented resolution which could further understanding of these complex diseases. Here, we apply single-cell RNA-sequencing to human inflamed intestine and show that the largest differences among patients are present within the myeloid compartment including macrophages and neutrophils. Using spatial transcriptomics in human tissue at single-cell resolution (CosMx Spatial Molecular Imaging) we spatially localize each of the macrophage and neutrophil subsets identified by single-cell RNA-sequencing and unravel further macrophage diversity based on their tissue localization. Finally, single-cell RNA-sequencing combined with single-cell spatial analysis reveals a strong communication network involving macrophages and inflammatory fibroblasts. Our data sheds light on the cellular complexity of these diseases and points towards the myeloid and stromal compartments as important cellular subsets for understanding patient-to-patient heterogeneity., This work was funded by grant PID2021-123918OB-I00 from MCIN/AEI/ 10.13039/501100011033 and co-funded by “FEDER A way to make Europe”. AM-C, VG and ID were funded by grant Grant #2008-04050 from The Leona and Harry B. Helmsley Charitable Trust. EM-A is funded by grant RH042155 (RTI2018-096946-B-I00) from Ministerio de Ciencia e Innovacion. IA-T is funded by grant 831434-2 (CE_IMI2-2018-14 call). HH received support for the project PID2020-115439GB-I00- funded by MCIN/AEI/10.13039/501100011033. This publication is part of a project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831434. This project also has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 848028.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Diagnostic performance of plasma Aß42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: an international multi-center study

  • Doecke, James D.
  • González Escalante, Armand
  • Contador, José
  • Suárez-Calvet, Marc
  • Fernández-Lebrero, Aida
  • Puig-Pijoan, Albert
  • Ortiz Romero, Paula, 1994-
  • Jiménez-Moyano, Esther
  • Minguillón, Carolina
  • Campo, Marta del
  • Teunissen, Charlotte E.
Introduction: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aß42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. Methods: Plasma samples (n = 1298) were collected from six international centers. Aß40, Aß42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut-off models. Results: p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aß- dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre-defined cut-offs. Discussion: p-tau181 was the best single plasma marker for detecting AD at any stage. Specific cut-offs are needed to maximize diagnostic performances. Highlights: Phosphorylated tau (p-tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co-pathology in frontotemporal dementia (FTD), p-tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD., O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens. L.G. participated on advisory boards for, and received writing honoraria and travel grants from, Almirall, Biogen, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, and Teva. Work at Lund University was supported by the European Research Council (ADG-101096455), Alzheimer's Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation (AF-980907), Swedish Brain Foundation (FO2021-0293), Parkinson foundation of Sweden (1412/22), Cure Alzheimer's fund, Rönström Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259), and Swedish federal government under the ALF agreement (2022-Projekt0080). The ALFA+ Study has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. M.S.-C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and ‘‘PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). Research of C.E.T. is supported by the European Commission (Marie Curie International Training Network), grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking [JU], grant No. 101034344) and JPND (bPRIDE), European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (22HLT07 NEuroBioStand), CANTATE project funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. C.T. is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). C.T. is recipient of TAP-dementia, a ZonMw funded project (#10510032120003) in the context of the Dutch National Dementia Strategy.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease

  • Mishra, Neha
  • Scherer, Michael
  • Rosenstiel, Philip
Background and aims: Treatment with tumor necrosis factor α (TNFα) antagonists in IBD patients suffers from primary non-response rates of up to 40%. Biomarkers for early prediction of therapy success are missing. We investigated the dynamics of gene expression and DNA methylation in blood samples of IBD patients treated with the TNF antagonist infliximab and analyzed the predictive potential regarding therapy outcome. Methods: We performed a longitudinal, blood-based multi-omics study in two prospective IBD patient cohorts receiving first-time infliximab therapy (discovery: 14 patients, replication: 23 patients). Samples were collected at up to 7 time points (from baseline to 14 weeks after therapy induction). RNA-sequencing and genome-wide DNA methylation data were analyzed and correlated with clinical remission at week 14 as a primary endpoint. Results: We found no consistent ex ante predictive signature across the two cohorts. Longitudinally upregulated transcripts in the non-remitter group comprised TH2- and eosinophil-related genes including ALOX15, FCER1A, and OLIG2. Network construction identified transcript modules that were coherently expressed at baseline and in non-remitting patients but were disrupted at early time points in remitting patients. These modules reflected processes such as interferon signaling, erythropoiesis, and platelet aggregation. DNA methylation analysis identified remission-specific temporal changes, which partially overlapped with transcriptomic signals. Machine learning approaches identified features from differentially expressed genes cis-linked to DNA methylation changes at week 2 as a robust predictor of therapy outcome at week 14, which was validated in a publicly available dataset of 20 infliximab-treated CD patients. Conclusions: Integrative multi-omics analysis reveals early shifts of gene expression and DNA methylation as predictors for efficient response to anti-TNF treatment. Lack of such signatures might be used to identify patients with IBD unlikely to benefit from TNF antagonists at an early time point., Open Access funding enabled and organized by Projekt DEAL. This work was supported by the EU projects SYSCID (733100), IMI2 ImmUniverse (853995), the IMI2 Project 3TR (831434), the BMBF project iTREAT (01ZX1902A), and ExC 2167 Precision Medicine in Chronic Inflammation (RTF-VI).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

  • Kerick, Martin|||0000-0002-6298-4514
  • Acosta-Herrera, Marialbert|||0000-0002-9868-6535
  • Simeón-Aznar, Carmen Pilar|||0000-0003-3390-9029
  • Callejas Rubio, Jose Luis|||0000-0002-1653-0087
  • Assassi, Shervin|||0000-0002-8059-9978
  • Carreira, Patricia E.|||0000-0001-8279-3806
  • Castellvi, Ivan|||0000-0002-5410-5807
  • Ríos, Raquel
  • García-Portales, Rosa
  • Fernández-Nebro, Antonio|||0000-0002-2962-9844
  • García-Hernández, Francisco Jose|||0000-0002-2600-0485
  • Aguirre, Mª Angeles|||0000-0002-5653-4293
  • Fernández-Gutiérrez, Benjamín
  • Rodriguez-Rodriguez, Luis|||0000-0002-2869-7861
  • García de la Peña-Lefebvre, Paloma
  • Vicente-Rabaneda, Esther Francisca
  • Andréu, José Luis|||0000-0002-6002-1239
  • Fernández de Castro, Mónica
  • López Longo, Francisco Javier
  • Fonollosa Pla, Vicent
  • Guillén-Del-Castillo, Alfredo|||0000-0003-0626-507X
  • Espinosa, Gerard|||0000-0003-1336-0163
  • Tolosa, Carlos
  • Pros, Ana|||0000-0003-0266-0531
  • Beltran Catalan, Emma|||0000-0001-8070-6916
  • Rodríguez-Carballeira, Mónica|||0000-0002-8802-0238
  • Narváez, Javier|||0000-0002-1614-8064
  • Rubio Rivas, Manuel|||0000-0002-9548-1374
  • Ortiz-Santamaría, Vera
  • Madroñero, Ana Belén
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
  • Díaz, Bernardino
  • Trapiella, Luis
  • Egurbide, María Victoria
  • Fanlo-Mateo, Patricia
  • Sáez-Comet, Luis|||0000-0002-9868-6498
  • Díaz, F.
  • Román-Ivorra, José Andrés
  • Alegre-Sancho, Juan José|||0000-0003-1641-0875
  • Freire, Mercedes
  • Garcia, Francisco J.B.
  • Oreiro, Natividad
  • Witte, Torsten
  • Kreuter, Alexander|||0000-0003-2275-499X
  • Riemekasten, Gabriela
  • Airò, Paolo
  • Magro-Checa, César
  • Voskuyl, A.E.|||0000-0002-9699-1827
  • Vonk, Madelon C.
  • Hesselstrand, Roger
  • Nordin, Annika|||0000-0003-1976-4679
  • Lunardi, Claudio|||0000-0001-6446-2990
  • Gabrielli, Armando
  • Hoffmann-Vold, A.
  • Distler, J.H.W.
  • Padyukov, Leonid|||0000-0003-2950-5670
  • Koeleman, B.P.C.
  • Proudman, Susanna M.
  • Nikpour, Mandana
  • Stevens, W.
  • Zochling, Jane M.
  • Sahhar, Joanne|||0000-0003-4220-2906
  • Roddy, J.
  • Nash, P.
  • Tymms, Kathleen
  • Rischmueller, Maureen
  • Lester, Susan Elizabeth
  • Vigone, Barbara
  • Pers, Jacques-Olivier|||0000-0001-7287-5541
  • Saraux, Alain
  • Devauchelle-Pensec, Valérie
  • Cornec, Divi|||0000-0002-9159-702X
  • Jousse-Joulin, Sandrine
  • Lauwerys, Bernard
  • Ducreux, Julie
  • Maudoux, Anne-Lise
  • Vasconcelos, Carlos
  • Tavares, Ana
  • Neves, Esmeralda
  • Faria, Raquel
  • Brandão, Mariana
  • Campar, Ana
  • Marinho, António
  • Farinha, Fátima
  • Almeida, Isabel
  • Blanco, Ricardo|||0000-0003-2344-2285
  • Corrales Martínez, Alfonso
  • Cervera, Ricard
  • Rodríguez-Pintó, Ignasi
  • Lories, Rik
  • De Langhe, Ellen|||0000-0002-4045-2146
  • Belz, Doreen
  • Baerlecken, Niklas
  • Stummvoll, Georg
  • Zauner, Michael
  • Lehner, Michaela
  • Collantes Estevéz, Eduardo|||0000-0002-7647-6289
  • Ortega Castro, Rafaela|||0000-0002-7552-3469
  • Escudero Contreras, Alejandro|||0000-0001-5891-5527
  • Castro-Villegas, Ma Carmen
  • Fernández Roldán, María Concepción
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Raya, Enrique
  • Jiménez Moleón, Inmaculada
  • de Ramon, Enrique
  • Díaz Quintero, Isabel
  • Meroni, Pier Luigi|||0000-0002-3394-1451
  • Gerosa, Maria|||0000-0001-5241-5847
  • Schioppo, Tommaso|||0000-0001-8359-5131
  • Artusi, Carolina
  • Chizzolini, Carlo
  • Zuber, Aleksandra
  • Wynar, Donatienne
  • Kovács, Laszló
  • Balog, Attila
  • Deák, Magdolna
  • Bocskai, Márta
  • Dulic, Sonja
  • Kádár, Gabriella
  • Hiepe, Falk|||0000-0003-3584-5292
  • Gerl, Velia
  • Thiel, Silvia
  • rodriguez Maresca, Manuel
  • López-Berrio, Antonio
  • Aguilar-Quesada, Rocío|||0000-0003-3125-6634
  • Navarro-Linares, Héctor
  • Hunzelmann, Nicolas
  • Moroncini, Gianluca|||0000-0002-0380-0105
  • de Vries-Bouwstra, Jeska K.
  • Orozco, Gisela|||0000-0002-3479-0448
  • Barton, Anne|||0000-0003-3316-2527
  • Herrick, Ariane|||0000-0003-4941-7926
  • Terao, Chikashi|||0000-0002-6452-4095
  • Allanore, Yannick|||0000-0002-6149-0002
  • Fonseca, Carmen
  • Alarcón-Riquelme, Marta E.|||0000-0002-7632-4154
  • Radstake, Timothy R.D.J.
  • Beretta, Lorenzo|||0000-0002-6529-6258
  • Denton, Christopher P.
  • Mayes, Maureen D.|||0000-0001-5070-2535
  • Martín, Javier|||0000-0002-2202-0622
Copy number (CN) polymorphisms of complement C4 play distinct roles in many conditions, including immune-mediated diseases. We investigated the association of C4 CN with systemic sclerosis (SSc) risk. Imputed total C4, C4A, C4B, and HERV-K CN were analyzed in 26,633 individuals and validated in an independent cohort. Our results showed that higher C4 CN confers protection to SSc, and deviations from CN parity of C4A and C4B augmented risk. The protection contributed per copy of C4A and C4B differed by sex. Stronger protection was afforded by C4A in men and by C4B in women. C4 CN correlated well with its gene expression and serum protein levels, and less C4 was detected for both in SSc patients. Conditioned analysis suggests that C4 genetics strongly contributes to the SSc association within the major histocompatibility complex locus and highlights classical alleles and amino acid variants of HLA-DRB1 and HLA-DPB1 as C4-independent signals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease

  • Garrido-Trigo, Alba
  • Corraliza, Ana Maria|||0000-0002-3067-7763
  • Veny, Marisol
  • Dotti, Isabella
  • Melón-Ardanaz, Elisa
  • Rill, Aina|||0000-0001-9885-0705
  • Crowell, Helena L.|||0000-0002-4801-1767
  • Corbí, Ángel|||0000-0003-1980-5733
  • Gudiño, Victoria
  • Esteller, Miriam
  • Álvarez-Teubel, Iris
  • Aguilar, Daniel
  • Masamunt, M.Carmen
  • Killingbeck, E.|||0000-0002-5108-5089
  • Kim, Youngmi
  • Leon, Michael|||0000-0003-3982-2063
  • Visvanathan, Sudha
  • Marchese, Domenica|||0000-0002-3036-4580
  • Caratù, Ginevra|||0000-0003-1085-8062
  • Martín Cardona, Albert|||0000-0002-7090-0106
  • Esteve, Maria|||0000-0001-7716-0027
  • Panés, Julián|||0000-0002-4971-6902
  • Ricart, Elena
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Heyn, Holger|||0000-0002-3276-1889
  • Salas, Azucena
Ulcerative colitis and Crohn's disease are chronic inflammatory intestinal diseases with perplexing heterogeneity in disease manifestation and response to treatment. While the molecular basis for this heterogeneity remains uncharacterized, single-cell technologies allow us to explore the transcriptional states within tissues at an unprecedented resolution which could further understanding of these complex diseases. Here, we apply single-cell RNA-sequencing to human inflamed intestine and show that the largest differences among patients are present within the myeloid compartment including macrophages and neutrophils. Using spatial transcriptomics in human tissue at single-cell resolution (CosMx Spatial Molecular Imaging) we spatially localize each of the macrophage and neutrophil subsets identified by single-cell RNA-sequencing and unravel further macrophage diversity based on their tissue localization. Finally, single-cell RNA-sequencing combined with single-cell spatial analysis reveals a strong communication network involving macrophages and inflammatory fibroblasts. Our data sheds light on the cellular complexity of these diseases and points towards the myeloid and stromal compartments as important cellular subsets for understanding patient-to-patient heterogeneity.